News Snapshot:
Share on WhatsApp Beijing: Chinese vaccine maker Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. has commenced the phase-3 clinical trials for its Covid-19 vaccine, planning to recruit 29,000 volunteers across the world. This is China’s first phase-3 efficacy study for a recombinant subunit COVID-19 vaccine candidate, the company said in a statement Thursday. Jointly developed by the company and the Institute of Microbiology under the Chinese Academy of Sciences, the vaccine was issued with a clinical research permit from the National Medical Products Administration June 19, reports Xinhua news agency. Researchers started phase-1 and phase-2 clinical trials on June 23, which...
